Cyanvac LLC

Cyanvac LLC, a minority-owned, Asian-Pacific American-owned sole proprietorship based in Athens, Georgia, is a federal grant recipient focused on viral vaccine development using the parainfluenza virus 5 (PIV5) vector platform to address respiratory and zoonotic pathogens. The vendor operates exclusively as a prime recipient on federally funded research grants; it holds no federal contracts and no subcontract awards in the source data.

Cyanvac's federal footprint consists of five grants totaling approximately $3.1 million in obligated dollars across three customer agencies over the past eight years. The vendor's most recent award is a $1.999997 million cooperative agreement from the U.S. Department of Agriculture Animal and Plant Health Inspection Service (APHIS) under CFDA 10.025 (Plant and Animal Disease, Pest Control, and Animal Care), awarded February 2, 2026, running through September 30, 2028. The scope centers on development and evaluation of a PIV5-vectored vaccine to protect poultry from highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5N1, including immunogenicity assessment, efficacy testing via in ovo and spray administration routes in naive and maternally antibody-exposed chickens and turkeys, and biodistribution and transmission studies — all conducted in an ABSL3 (Biosafety Level 3) facility in Athens. Prior work includes two National Institute of Allergy and Infectious Diseases (NIAID) grants under R21 and Phase I SBIR mechanisms: a bivalent RSV/HMPV intranasal vaccine project awarded September 5, 2023 (completion August 31, 2026), and a Phase I SBIR for an HMPV candidate vaccine awarded May 5, 2023 (completion October 31, 2024). Cyanvac also received a Phase I SBIR from NIAID in August 2022 for liquid formulation development of CVXGA1, its PIV5-vectored COVID-19 intranasal vaccine candidate currently in Phase 1 clinical testing. The vendor's technology platform leverages PIV5 as a safe, genetically stable delivery vector with demonstrated immunogenicity in animal models and early human trials; multiple vaccine constructs are in clinical development or late-stage preclinical evaluation. One award reaches ultimate completion within the next twenty-four months, representing potential recompete opportunity.